These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 20173735)

  • 21. The role of ITPA and ribavirin transporter genes polymorphisms in prediction of ribavirin-induced anaemia in chronic hepatitis C Egyptian patients.
    El Desoky ES; Abdelhafez AT; Cusato J; Kamel SI; Hussein AM; De Nicolo A; Di Perri G; D'Avolio A
    Clin Exp Pharmacol Physiol; 2017 Sep; 44(9):965-968. PubMed ID: 28543275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection.
    Maan R; van der Meer AJ; Brouwer WP; Plompen EP; Sonneveld MJ; Roomer R; van der Eijk AA; Groothuismink ZM; Hansen BE; Veldt BJ; Janssen HL; Boonstra A; de Knegt RJ
    PLoS One; 2015; 10(10):e0139317. PubMed ID: 26441325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens.
    Vasanthakumar A; Davis JW; Abunimeh M; Söderholm J; Zha J; Dumas EO; Cohen DE; Waring JF; Lagging M
    PLoS One; 2018; 13(5):e0198296. PubMed ID: 29851985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.
    Clark PJ; Aghemo A; Degasperi E; Galmozzi E; Urban TJ; Vock DM; Patel K; Thompson AJ; Rumi MG; D'Ambrosio R; Muir AJ; Colombo M
    J Viral Hepat; 2013 Dec; 20(12):858-66. PubMed ID: 24304455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment.
    Lin JJ; Loucks CM; Trueman JN; Drögemöller BI; Wright GEB; Yoshida EM; Ford JA; Lee SS; Kim RB; Al-Judaibi B; Schwarz UI; Ramji A; Tam E; Ross CJ; Carleton BC
    Biomed Pharmacother; 2021 Nov; 143():112195. PubMed ID: 34562771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.
    Holmes JA; Roberts SK; Ali RJ; Dore GJ; Sievert W; McCaughan GW; Crawford DH; Cheng WS; Weltman MD; Bonanzinga S; Visvanathan K; Sundararajan V; Desmond PV; Bowden DS; Matthews GV; Thompson AJ;
    Hepatology; 2014 Jun; 59(6):2152-60. PubMed ID: 24449403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C).
    Birerdinc A; Estep M; Afendy A; Stepanova M; Younossi I; Baranova A; Younossi ZM
    J Viral Hepat; 2012 Jun; 19(6):414-22. PubMed ID: 22571903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allelic inhibition of displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms.
    Galmozzi E; Facchetti F; Degasperi E; Aghemo A; Lampertico P
    J Virol Methods; 2013 Feb; 187(2):271-3. PubMed ID: 23201294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines.
    Jimmerson LC; Clayton CW; MaWhinney S; Meissner EG; Sims Z; Kottilil S; Kiser JJ
    Antiviral Res; 2017 Feb; 138():79-85. PubMed ID: 27956135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C.
    Delvaux N; Costa VD; Costa MM; Villar LM; Coelho HS; Esberard EB; Flores PP; Brandão-Mello CE; Villela-Nogueira CA; Almeida AJ; Lampe E
    Mem Inst Oswaldo Cruz; 2015 Aug; 110(5):636-43. PubMed ID: 26154744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens.
    Coppola N; De Pascalis S; Messina V; Di Caprio G; Martini S; de Stefano G; Starace M; Stornaiuolo G; Stanzione M; Ascione T; Minichini C; Sangiovanni V; Zampino R; Calò F; Rinaldi L; Persico M; Federico A; Buonomo AR; Borgia G; Gaeta GB; Filippini P; Gentile I
    Antivir Ther; 2017; 22(7):551-558. PubMed ID: 28165327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir.
    Boglione L; De Nicolò A; Cusato J; Cariti G; Di Perri G; D'Avolio A
    J Viral Hepat; 2014 Apr; 21(4):260-3. PubMed ID: 24597694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High Prevalence of ITPA Alleles Associated with Ribavirin-Induced Hemolytic Anemia Among Mexican Population.
    Gonzalez-Aldaco K; Rebello Pinho JO; Panduro A; Martinez-Lopez E; Gleyzer K; Fierro N; Roman S
    Ann Hepatol; 2017; 16(2):221-229. PubMed ID: 28233743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients.
    Scherzer TM; Stättermayer AF; Stauber R; Maieron A; Strasser M; Laferl H; Schwarzer R; Datz C; Rutter K; Beinhardt S; Steindl-Munda P; Hofer H; Ferenci P
    J Hepatol; 2013 Nov; 59(5):964-71. PubMed ID: 23850877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics of ribavirin-induced anemia in HCV patients.
    D'Avolio A; Cusato J; De Nicolò A; Allegra S; Di Perri G
    Pharmacogenomics; 2016 Jun; 17(8):925-41. PubMed ID: 27248282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of inosine triphosphatase activity during ribavirin treatment for chronic hepatitis C.
    Tanaka Y; Yokomori H; Otori K
    Clin Chim Acta; 2018 Jul; 482():16-20. PubMed ID: 29580856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical importance of pharmacogenetics in the treatment of hepatitis C virus infection.
    Kamal AM; MitruŢ P; Kamal KC; Tica OS; Niculescu M; Alexandru DO; Tica AA
    Rom J Morphol Embryol; 2016; 57(2 Suppl):675-680. PubMed ID: 27833958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.
    Tanaka Y; Kurosaki M; Nishida N; Sugiyama M; Matsuura K; Sakamoto N; Enomoto N; Yatsuhashi H; Nishiguchi S; Hino K; Hige S; Itoh Y; Tanaka E; Mochida S; Honda M; Hiasa Y; Koike A; Sugauchi F; Kaneko S; Izumi N; Tokunaga K; Mizokami M
    Hum Mol Genet; 2011 Sep; 20(17):3507-16. PubMed ID: 21659334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.
    Rallón NI; Morello J; Labarga P; Benito JM; Rodríguez-Nóvoa S; Vispo E; Barreiro P; Castro MÁ; Aguirrebengoa K; Pineda JA; Miralles P; Tellez MJ; Portu J; Miralles C; Ocampo A; Soriano V;
    Clin Infect Dis; 2011 Dec; 53(12):1291-5. PubMed ID: 22028438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.
    Seto WK; Tsang OT; Liu K; Chan JM; Wong DK; Fung J; Lai CL; Yuen MF
    J Viral Hepat; 2013 Jul; 20(7):470-7. PubMed ID: 23730840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.